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Summary
Background. There is a need for reliable predictors of breast cancer aggressiveness that will further refine the staging
classification and help guide the implementation of novel therapies. We have identified RhoC as being nearly always
overexpressed in the most aggressive form of breast cancer, inflammatory breast cancer (IBC); in subsequent work
we identified RhoC to be a promising marker of aggressive behavior in breast cancers less than 1 cm in diameter.
We hypothesized that RhoC expression would identify aggressive, non-IBC tumors breast cancer patients at any
stage with worse outcomes defined as recurrence and/or metastasis.
Methods. We constructed four high-density tissue microarrays (TMAs) using 801 tissue cores from 280 patients.
These tissues represent a wide range of normal breast and breast disease, including intraductal hyperplasia, ductal
carcinoma in situ (DCIS), invasive carcinomas, and distant metastases. The TMAs were immunostained using a
polyclonal anti-RhoC antibody developed in our laboratory. Cytoplasmic RhoC expression was scored as negative,
weak, moderate, or strong by a previously validated scoring schema.
Results. RhoC expression increases with breast cancer progression. All samples of normal breast epithelium had
negative to weak staining, whereas staining intensity increased in hyperplasia, DCIS, invasive carcinoma, and
metastases (Kruskal–Wallis p < 0.001). In patients with invasive carcinoma, high RhoC expression was associated
with features of aggressive behavior including high histologic grade, positive lymph nodes, and negative hormonal
receptor status. High RhoC expression was a predictor of overall survival in patients with breast cancer (log rank
test, p = 0.002) and was associated with 100% increase in the risk of death as compared to patients with low RhoC
expression. Importantly, high RhoC was an independent predictor of poor response to doxorubicin-based che-
motherapy with a hazard ratio of 3.1 and a 95% CI of 1.2–7.7 (p = 0.02).
Conclusion. RhoC expression increases with breast cancer progression and RhoC protein level in tumor tissue is
strongly associated with biologically aggressive invasive carcinomas of the breast. RhoC expression, if validated,
may identify patients who are less likely benefit from doxorubicin therapy and suggests RhoC overexpression as a
new target for intervention.
Introduction
Breast cancer remains the second most common cause of
cancer related deaths for women in the United States [1].
With the most advanced current treatment options, it is
a fact that once patients develop distant metastases, they
succumb to the disease [2]. The most important prog-
nostic indicators in breast cancer that are in current use
in the clinic are components of the staging system, such
as primary tumor size and the presence of lymph node
metastases [3]. Although these parameters are the most
powerful prognostic factors available, they are not as
precise as desired in predicting which tumors will recur
locally and/or metastasize distally [4]. There are small
invasive carcinomas that follow an aggressive clinical
course and large tumors that do not recur or metasta-
size. Approximately one-third of women with
node-negative breast cancer experience recurrences,
whereas approximately one-third of patients with posi-
tive lymph nodes are free of disease 10 years after the
primary tumor diagnosis. In addition to size and lymph
nodes, other morphologic features, such as histological
grade, vascular invasion, and molecular markers have
been investigated for their potential to predict outcome,
but in general, they have had limited value so far [4–6].
These data highlight the need for more sensitive and
specific markers of aggressive behavior.
Through a modified version of the differential display
technique and in situ hybridization of breast tissues, we
previously identified RhoC, a gene involved in cell
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polarity and motility, as being overexpressed in the most
lethal form of locally advanced breast cancers, inflam-
matory breast cancer (IBC) [7]. We demonstrated that
RhoC functions as a transforming oncogene for human
mammary epithelial cells giving rise to a highly motile
and invasive phenotype [8,9]. Invasive breast carcinomas
that developed metastases exhibited higher levels of
RhoC protein than invasive carcinomas that did not
metastasize [10]. This body of work led us to hypothe-
size that RhoC overexpression may occur early in breast
cancer progression and that it may identify a group of
invasive, non-IBC tumors with a highly aggressive
phenotype.
Methods
Selection of patients and tissue microarray development
Breast tissues were obtained from the Surgical Pathol-
ogy files at the University of Michigan with Institutional
Review Board approval. A total of 280 cases (n = 801
tissue microarray elements) were reviewed by the study
pathologist (CGK) and arrayed in four high-density
tissue microarrays (TMAs), as previously described
[11,12]. At least three tissue cores (0.6 mm diameter)
were sampled from each block to account for tumor
heterogeneity. The TMAs contained the whole spectrum
of breast pathology, with samples of normal breast
(n = 76), intraductal hyperplasia (n = 26), ductal car-
cinoma in situ (n = 22), invasive carcinoma (n = 639),
and breast cancer metastases (n = 38). The invasive
carcinomas were obtained from 233 largely consecutive
patients (n = 639 tissue microarray elements) with
follow-up information at the University of Michigan
between 1987 and 1991. Clinical and outcome infor-
mation on the 233 patients was obtained by chart review
performed by the surgeon on the study (MSS) with IRB
approval. In our cohort of 233 breast cancer patients,
211 had follow-up information. The median duration of
follow-up was 3.6 years (range 15 days–17 years).
Clinical and pathological variables were determined
following well-established criteria. The histologic grade
was assessed according to the method described by
Elston and Ellis [13]; angiolymphatic invasion was
classified as either present or absent.
Immunohistochemical studies
Immunohistochemistry was performed on the TMAs by
using a standard biotin–avidin complex technique and a
polyclonal antibody against RhoC that was previously
validated by immunoblot and immunohistochemistry
[10]. RhoC expression was evaluated at least three times
for every tissue microarray element and at least nine
times for each tumor, using an internet based tool (TMA
Profiler, University of Michigan, Ann Arbor, MI)
[11,14]. Using this method, the pathologist is blinded to
tumor stage and clinical information. The median value
of all measurements from a single individual was used for
subsequent analyses. As observed previously [10], RhoC
protein was strongly expressed in the cytoplasm of
myoepithelial cells and vascular smooth muscle cells,
which served as consistent internal positive controls.
Cytoplasmic RhoC expression was scored from 1 to 4 by
comparison to the positive internal controls [10,11,15].
Strong, diffuse staining was considered score = 4,
whereas moderate and low diffuse staining was scored as
3 and 2, respectively. Negative staining was scored as 1.
Based on our previous work dealing with the biological
characterization of RhoC as an oncogene, we defined
high RhoC expression when there was strong staining
(score = 4) and low RhoC expression, when staining
was negative, weak, or moderate (scores = 1–3).
Statistical analysis
The association between RhoC protein expression and
the pathologic diagnoses of the tissue microarray ele-
ment was assessed using the general estimating equation.
The ordinal expression categories for RhoC were mod-
eled using the multinomial distribution with the cumu-
lative logit link. Tissue microarray elements were
clustered by patient. The model calculates the odds of a
higher expression score versus a lower score, with the
odds ratio and 95% confidence intervals reported.
The median RhoC expression score by patient was
calculated for the subset of invasive carcinoma micro-
array elements. In instances where the calculated median
was the midpoint between expression categories, the
median was rounded to the higher category. Possible
associations between the median RhoC expression score
and clinical and pathologic features of the patient were
assessed using the cumulative-logit multinomial model.
Also called the proportional-odds model, the model
calculates the odds of a higher expression score com-
pared to a lower score across the ordinal categories of
expression. The appropriateness of the proportional-
odds assumption across categories was tested using the
v2 score test. The odds ratio and 95% confidence inter-
vals are reported.
Overall survival time, time to breast cancer specific
mortality, and time to treatment failure were calculated
from the date of surgery until the subjects’ date of death,
date of death due to breast cancer, or the date of diag-
nosed treatment failure, respectively. Patients experi-
encing competing events were censored at the date of the
competing event. For example, for calculations of breast
cancer specific mortality, patients dying from other
causes were censored on that date. Treatment failures
included the diagnosis of local recurrence and the
development of regional and distant metastases. Patients
not experiencing any failure events were censored on
their last date of follow-up or date of death. The ana-
lyzable sample included those patients with primary
invasive tumor specimens arrayed for whom clinical
follow-up data were available (N = 211).
Univariate associations between time-to-event end-
points and the clinical and pathologic characteristics,
102 CG Kleer et al.
which included median RhoC expression, were assessed
using the log-rank test statistic. The probability of
events was estimated using the product-limit method of
Kaplan and Meier. Multivariate associations were
modeled using Cox proportional hazards regression.
Clinical and pathologic characteristics with univariate
log-rank test statistics with p-values less than 10% were
included in multivariate models. The most parsimonious
multivariate models were constructed using backward,
stepwise elimination, with a p-value less than or equal to
5% necessary for a covariate to be retained. Hazard
ratios and 95% confidence intervals are reported.
Results
RhoC protein expression is elevated in breast cancer
On the basis of our previous work characterizing RhoC
as an oncogene in IBC and its protein expression in
breast tissues, we sought to determine whether RhoC is
upregulated as breast cancer develops. To this end, we
evaluated the expression of RhoC protein in a wide
range of breast tissues (280 cases, n = 801 tissue
microarray elements) by immunohistochemistry, to
characterize its expression in situ. RhoC expression was
observed mainly in the cytoplasm (Figure 1(a)), consis-
tent with our previous observations [10]. Invasive breast
carcinomas that expressed high levels of RhoC and
those that expressed low levels of RhoC were readily
apparent. RhoC protein levels were elevated in invasive
carcinoma when compared to normal, intraductal
hyperplasia, and DCIS (Table 1 and Figure 1). The
odds of a higher RhoC expression levels were 2 times, 8
times, 12 times, and 8 times higher than normal epi-
thelium, for intraductal hyperplasia, DCIS, invasive
carcinoma, and metastatic deposits, respectively
(Table 2).
Elevated RhoC expression is associated with aggressive
breast cancer and poor prognosis
By using our breast cancer tissue microarray data, we
evaluated the clinical pathological associations of RhoC
Figure 1. RhoC protein expression increases with breast cancer progression. (a) Tissue microarray samples of a normal breast lobule (1) and
intraductal hyperplasia (2) with negative and weak RhoC expression. Ductal carcinoma in situ with comedo-necrosis (3) and invasive ductal
carcinoma (4) with moderate and high RhoC expression, respectively. High power magnification of an invasive ductal carcinoma showing
cytoplasmic accumulation of RhoC protein (5) Metastatic breast carcinoma in bone (6) with high expression of RhoC. (b) Mean RhoC expression
increases with the severity of the diagnosis. Original magnification 40· and 100·.
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protein levels in breast cancer. In our cohort of 233
breast cancer patients (n = 801 samples), 211 had
follow-up information. The median age of the study
population was 58 years (range 28–99 years). The clin-
ical and pathological characteristics of the patients are
summarized in Table 3. The breakdown of treatment
modalities in this group of patients is summarized in
Table 4. Ninety-three patients (44.1%) received chemo-
therapy following surgery. In 90 of 93 patients (97%) the
treatment consisted of a doxorubicin and cyclophos-
phamide combination regimen, with the remaining three
patients receiving taxol alone.
After a median follow-up of 3.6 years (range: 15
days–17 years), 42 of the 226 patients (18.6%) died of
breast cancer. The 5- and 10-year disease specific sur-
vival rates for the entire cohort of patients were 60% and
38%, respectively.
High RhoC expression was present in a subset of
invasive carcinomas (13 of 211, 6.2%). The association
between RhoC protein levels and clinical characteristics
is shown on Table 5. RhoC expression was strongly
associated with the presence of positive axillary lymph
nodes (Fisher’s exact test, p = 0.0026), one of the
strongest known predictors of survival. High RhoC
expression was also associated with increasing histologic
tumor grade (Fisher’s exact test, p = 0.016), a measure
of the degree of tumor differentiation and poor prog-
nostic indicator. Grade II and III tumors were three and
six times more likely to have a high RhoC expression
when compared to grade I tumors, respectively. High
RhoC expression was associated with negative estrogen
receptor status (Fisher’s exact test, p = 0.033) and
negative progesterone receptor status (Fisher’s exact
test, p = 0.004). Notably, despite the small number of
tumors, RhoC overexpression was strongly associated
with features of poor outcome in patients with breast
cancer.
We next investigated the prognostic value of RhoC
protein expression by interrogating the dataset about its
prediction of aspects of the outcome in patients with
newly diagnosed breast cancer. As expected, at the
univariate level, the stage of disease, lymph node status,
and histological tumor grade were associated with
overall and disease-specific survival (Tables 6 and 7).
Hormone receptor status was inversely associated with
outcome. We found a strong and consistent association
between RhoC protein levels and overall patient out-
come. Higher RhoC protein levels were associated with
all the important clinical outcomes that comprise poor
prognosis’: shorter disease-free interval after initial
surgical treatment, lower overall survival, and a high
probability of breast cancer-specific death (Figure 2).
The 10-year overall survival for patients with tumors
expressing high RhoC levels was 23% and by contrast to
53% for low levels of RhoC (log rank, p = 0.002, Fig-
ure 2b).
The best multivariable model predictive of overall
survival included tumor stage, negative PR, the presence
of vascular invasion, and treatment with radiotherapy,
chemotherapy and tamoxifen (Table 8). High RhoC
expression was a marginally significant independent
predictor of outcome. Patients with high RhoC levels
had a 100% higher risk of death when compared to
patients with low RhoC expression (hazard ratio 2, 95%
CI 1.0–4.1, p = 0.067).
RhoC is a promising predictive factor of response
to doxorubicin-based chemotherapy
In our cohort of 211 breast cancer patients, 93 (44.1%)
received adjuvant chemotherapy consisting in 90 of the
93 patients of a doxorubicin and cyclophosphamide
combination regimen (Table 4). We sought to determine
whether RhoC expression could predict survival in
chemotherapy treated patients. Tumor stage, positive
lymph node status, estrogen and progesterone receptor
status, lymphovascular invasion, tamoxifen use, and
median RhoC expression all had significant univariate
associations with survival for chemotherapy treated
patients. The multivariate model indicates that median
RhoC expression was found to be independently
Table 1. Frequency of RhoC protein expression in breast tissue samples as determined by immunohistochemistry
Breast tissue Cores Staining intensity, n (%) Mean intensity
1 2 3 4
Normal epithelium 76 58 (76) 16 (21) 2 (3) 0 1.26
Intraductal hyperplasia 26 14 (54) 11 (42) 1 (4) 0 1.50
Ductal carcinoma in situ 22 6 (27) 9 (41) 7 (32) 0 2.05
Invasive carcinoma 639 140 (22) 249 (39) 203 (32) 47 (7) 2.25
Metastasis 38 12 (32) 13 (34) 13 (34) 0 2.03
Total 801 2.11
Table 2. Odds of higher RhoC expression according to the tissue
diagnosis
Diagnosis Odds ratio 95% CI p-Value
Normal epithelium 1.00
Intraductal hyperplasia 2.46 1.01–6.00 0.0487
Ductal carcinoma in situ 8.41 3.35–21.14 <0.0001
Invasive carcinoma 12.16 7.00–21.14 <0.0001
Metastasis 8.03 3.64–17.70 <0.0001
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associated with overall survival following chemother-
apy, with a hazard ratio of 3.1 and a 95% CI of 1.2–7.7
(p = 0.0176) (Table 9).
Discussion
In this study based on unselected patients with primary
invasive carcinomas of the breast treated by standard of
care at our institution between 1987 and 1991, we tested
the hypothesis that RhoC protein levels are associated
with highly aggressive breast cancer. Furthermore, we
examined the expression of RhoC in the whole spectrum
of breast tissues, ranging from normal breast, intra-
ductal hyperplasia, ductal carcinoma in situ, invasive
carcinomas, and breast cancer metastases. We found
that a high level (4+) of RhoC protein is present only in
invasive carcinomas and not present in normal breast
epithelium, hyperplasia, or ductal carcinoma in situ.
RhoC protein expression increased steadily from normal
breast, to fibrocystic changes, to DCIS, and inva-
sive carcinomas. The strongest RhoC expression was
observed in locally advanced breast cancer and in
Table 4. Treatment characteristics of the patients with invasive carci-
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metastatic breast cancer. These findings suggest that
accumulation of RhoC protein is an early and progres-
sive event in the development of breast cancer, thereby
justifying efforts aimed at developing novel therapeutic
interventions that may prevent the increase in RhoC
protein expression.
In the group of patients with invasive carcinomas,
very high RhoC expression occurred in a small subset
(13 of 211, 6.2%). However, those patients with high
levels of RhoC protein in the tumor cells had uni-
formly a worse outcome than patients with low RhoC
expression, despite of aggressive multimodality treat-
ment. Consistently, high RhoC expression was associ-
ated with positive lymph nodes, higher histologic
grade, and with negative ER and PR protein expres-
sion, all known markers of more aggressive disease.
Patients with high RhoC expression had a 5- and
10-year overall survival of 57.5% and 23%, respectively,
in contrast to patients with low RhoC expression, who
had a 5- and 10-year overall survival of 70.5% and
53%, respectively (log rank test, p = 0.002). In the
multivariable Cox regression analysis, patients with
high RhoC levels had 100% increase in the risk of
death as compared to patients with low RhoC levels
(hazard ratio of 2, 95% CI of 1–4.1, p = 0.067). This
suggests that RhoC overexpression is a specific alter-
ation that occurs infrequently in early breast ancer, but
when present, it signals a biologically aggressive tumor
phenotype with high likelihood of recurrence and poor
survival despite different treatment interventions. We
suggest that this finding is clinically highly relevant
and, if further validated, it may be the basis of a new
clinically applicable test.
Notably, when we analyzed the predictive value of
RhoC in a group of breast cancer patients treated
uniformly with a combination regimen of doxorubicin
and cyclophosphamide, high RhoC levels were inde-
pendently associated with overall survival after che-
motherapy. Although the number of patients with high
RhoC expression is low overall, our data suggest that
RhoC may identify a small group of patients who have
a poor survival despite doxorubicin-based chemother-
apy. This is clinically relevant because, if further vali-
dated in a larger cohort of uniformly treated patients,
it may identify patients who might benefit from other
chemotherapeutic agents or alternative molecular
Table 5. Association of RhoC expression with other clinical and pathologic features
Characteristic: Fisher’s exact
p-value
Median RhoC Staining Intensity, N (%)
1 2 3 4
Tumor stage: 0.8520
1 11 (33.3) 33 (35.1) 17 (23.9) 4 (30.8)
2 10 (30.3) 29 (30.9) 29 (40.9) 4 (30.8)
3 9 (27.3) 17 (18.1) 17 (23.9) 4 (30.8)
4 0 3 (3.2) 2 (2.8) 0
Tumor size (cm): 0.5792
£ 2 11 (33.3) 38 (40.4) 32 (45.1) 4 (30.8)
>2 19 (57.6) 51 (54.3) 32 (45.1) 7 (53.9)
Tumor grade: 0.0166
I 8 (24.2) 13 (13.8) 3 (4.2) 0
II 14 (42.4) 43 (45.7) 31 (43.7) 4 (30.8)
III 9 (27.3) 29 (30.9) 30 (42.3) 9 (69.2)
Positive lymph nodes: 0.0026
Zero 16 (48.5) 45 (47.9) 26 (36.6) 5 (38.5)
1–3 4 (12.1) 19 (20.2) 21 (29.6) 2 (15.4)
4+ 9 (27.3) 10 (10.6) 16 (22.5) 4 (30.8)
Lymphovascular invasion: 0.6962
Present 10 (30.3) 23 (24.5) 22 (31.0) 6 (46.2)
Absent 23 (69.7) 69 (73.4) 48 (67.6) 7 (53.9)
Estrogen receptor: 0.0336
Positive 23 (69.7) 65 (69.2) 46 (64.8) 3 (23.1)
Negative 10 (30.3) 26 (27.7) 22 (31.0) 10 (76.9)
Progesterone receptor: 0.0043
Positive 22 (66.7) 55 (58.5) 35 (49.3) 1 (7.7)
Negative 11 (33.3) 35 (37.2) 34 (47.9) 12 (92.3)
Her2/Neu expression: 0.6965
Positive 4 (12.1) 15 (15.9) 15 (21.1) 2 (15.4)
Negative 29 (87.9) 73 (77.6) 52 (73.2) 11 (84.6)
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therapies. More research is needed in this direction to
further define the prognostic utility of RhoC.
The clinical significance of elevated RhoC protein in
breast cancer is linked to and completely consistent with
its biological functions. RhoC is a ras homology gene,
with highly conserved motifs and shares a high degree of
homology to RhoA, another member of the family
[16–18]. Rho proteins in general, and RhoC and RhoA in
particular, are involved in cytoskeletal reorganization,
specifically in the formation of actin stress fibers and
focal adhesion contacts [16–18]. When immortalized
human mammary epithelial cells are transfected
with RhoC, they undergo a striking change in the
cytoplasmic shape and they become motile and invasive
[9]. In our laboratory, we discovered the strong link be-
tween RhoC overexpression and inflammatory breast
cancer, the most aggressive form of locally advanced
breast cancer known [7–9,19]. Thus, it is not surprising
that RhoC overexpression occurs in a small group of
biologically aggressive non-IBC tumors with high pro-
pensity to recur and metastasize and which respond
poorly to doxorubicin-based adjuvant treatment.
Recently, Rho proteins have been implicated in breast
tubulogenesis and differentiation, probably through reg-
ulation of cell contractility [20]. Our descriptive obser-
vations support this notion since RhoC protein levels
increased with decreasing differentiation of the invasive
carcinomas. For example, well-differentiated invasive
carcinomas with prominent tubule formation, monoto-
nous appearing cells, and rare mitoses expressed little or
no RhoC protein whereas poorly differentiated carcino-
mas that grew in disorganized sheets of pleomorphic
malignant cells and exhibited a brisk mitotic activity ex-
pressed high levels of RhoC protein.
Since our initial reports of RhoC overexpression in
breast cancer our findings have been supported by other
investigations. RhoC overexpression has been found
in malignancies derived from different cell lineages
including non-small cell lung carcinoma, hepatocellular
carcinoma, ovarian carcinoma, melanoma, pancreatic
carcinoma, and gastric carcinoma [7,10,21–29]. In these
malignancies, RhoC has been implicated in neoplastic
transformation, progression, invasion, and metastases.
Taken together, these data suggest that RhoC may be
involved in a global, rather than a tissue type specific
mechanism of tumor progression.
Rho proteins are prenylated in order to exert
their functions and to localize appropriately to the sub
Table 6. Univariate analysis of overall survival
Characteristic 5-year 10-year Log-rank p-value
Estimate 95% CI Estimate 95% CI
Tumor stage <0.0001
1 83.5 73.5–93.5 71.8 59.0–84.6
2 78.2 68.0–88.4 53.2 40.0–66.4
3 or 4 47.5 33.3–61.5 33.3 19.0–47.8
Estrogen receptor 0.0078
Positive 75.0 66.9–83.0 55.8 45.9–65.7
Negative 57.0 44.7–62.3 39.4 26.6–52.2
Progesterone 0.0001
Positive 80.1 71.9–88.3 62.4 51.7–73.0
Negative 57.0 46.3–67.7 37.4 26.2–48.5
Lymphovascular invasion 0.0080
Absent 74.1 66.2–82.0 59.4 50.1–68.8
Present 59.9 47.4–72.3 34.7 21.6–47.9
Tumor grade 0.0245
I/II 78.1 69.9–86.4 58.8 48.2–69.3
III 60.2 48.9–71.5 42.0 30.1–54.0
Positive lymph nodes 0.0010
Zero 82.4 73.9–90.9 66.5 55.3–77.7
1–3 78.1 65.3–90.8 56.3 39.7–72.9
4+ 53.7 37.3–70.0 37.4 19.8–54.9
Tamoxifen use 0.0447
Yes 83.4 75.4–91.5 61.1 49.4–72.7
No 62.0 52.1–71.9 45.1 34.5–55.8
Median RhoC expression
1 80.8 65.1–96.5 58.0 35.9–80.1 0.0209
2 69.3 59.6–79.1 48.5 37.4–59.7
3 67.6 55.8–79.5 56.9 43.7–70.1
Low (1, 2, or 3) 70.5 63.7–77.3 52.9 44.9–60.9
High (4) 57.5 28.9–86.1 23.0 0.0–50.2
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Table 7. Univariate analysis of disease free survival
Characteristic 5-year 10-year Log-rank p-value
Estimate 95% CI Estimate 95% CI
Tumor stage <0.0001
1 96.1 90.8–100 90.6 81.8–100
2 85.7 77.0–94.4 67.3 54.0–80.5
3 or 4 59.4 44.3–74.4 48.2 31.5–64.9
Tumor size (cm)
£ 2 90.0 83.2–96.7 81.1 71.5–90.7 0.0500
>2 74.3 64.3–84.3 66.5 55.0–78.1
Tumor grade 0.0500
I/II 90.6 84.7–96.6 77.8 68.1–87.5
III 69.3 58.3–80.3 59.5 47.2–71.9
Positive lymph nodes <0.0001
Zero 93.5 87.9–99.0 86.0 77.3–94.7
1–3 82.3 70.4–94.3 67.8 51.5–84.2
4+ 62.0 45.4–78.6 46.5 26.9–66.1
Estrogen receptor 0.0041
Positive 86.6 80.1–93.0 74.5 65.4–83.7
Negative 64.9 52.4–77.3 54.4 40.4–68.6
Progesterone 0.0003
Positive 92.4 86.9–97.9 79.4 69.8–89.1
Negative 65.1 54.3–75.8 55.2 43.1–67.4
Lymphovascular invasion <0.0001
Absent 87.0 80.8–93.3 79.3 71.0–87.5
Present 64.4 51.8–76.9 47.3 32.8–61.8
Tamoxifen use 0.0121
Yes 87.8 80.7–95.0 80.9 71.6–90.2
No 74.9 65.8–84.1 60.2 48.9–71.6
Median RhoC expression 0.0736
1 92.1 83.1–100 72.7 51.4–94.0
2 80.2 71.4–89.0 72.8 62.2–83.4
3 78.7 68.3–89.1 68.6 55.7–81.6
Low (1, 2, or 3) 81.5 75.5–87.4 71.6 63.9–79.2
High (4) 64.7 36.2–93.2 32.4 0.0–67.1
Figure 2. RhoC protein expression is associated with survival in patients with breast cancer. (a) Tissue microarray elements containing repre-
sentative invasive carcinomas with negative (1), weak (2), moderate (3), and strong (4) RhoC staining intensities. Original magnification 40·. (b)
High RhoC expression in invasive carcinomas is associated with worse overall, disease-free, and survival following doxorubicin and
cyclophosphamide treatment.
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cytoplasmic membrane space [30–34]. Prenylation can
be inhibited by farnesyl transferase inhibitors (FTIs)
and FTIs are effective in modulating tumor growth in
ras-transformed tumor cells [35–39]. Our group has
previously found that FTIs were able to reverse of the
RhoC-induced phenotype (even though RhoC is not
itself farnesylated), manifested by a significant decrease
in anchorage-independent growth, motility, and inva-
sion [39]. Thus, we suggested that FTIs may be useful
therapeutic compounds in RhoC overexpressing tumors.
Another potentially useful strategy against RhoC phe-
notypes is represented by the HMGCoA (3-hydroxy-3-
methylglutaryl-CoA) reductase inhibitors (statins). In
particular, atorvastatin has been clearly shown to inhibit
RhoC driven phenotypes in melanoma cells [40].
In summary, we discovered that RhoC expression
increases with breast cancer progression and that it is
associated with markers of aggressive disease and poor
survival. Importantly, we found that RhoC overex-
pression is a negative predictor of response to doxoru-
bicin and cyclophosphamide. This work supports that
RhoC may have a role in the genesis of a highly
aggressive doxorubicin resistant breast cancer pheno-
type. Our finding that RhoC overexpression is an
infrequent and specific marker of aggressive breast
cancer with poor outcome despite treatment may have
important clinical implications. Specifically, RhoC
detection at the time of primary tumor diagnosis may, in
the future, aid clinicians in guiding treatment and paves
the way to the development of targeted treatments.
While our results are promising, RhoC expression needs
to be validated in relationship to outcome in the context
of cohorts treated in controlled clinical trials where all
patients are treated uniformly. If confirmed, application
of RhoC immunohistochemical analysis would be
technically straightforward and feasible.
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